Biohaven (BHVN) Common Equity (2021 - 2026)

Biohaven has reported Common Equity for 6 years, with the latest figure at $129.5 million in Q1 2026.

• Quarterly Common Equity rose 177297.26% year-over-year to $129.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $129.5 million (up 177297.26% YoY) and the FY2025 annual result came in at $52.1 million, up 103.87% from the prior year.
• Common Equity advanced to $129.5 million in Q1 2026 per BHVN's latest filing, from $52.1 million in the prior quarter.
• Over five years, Common Equity peaked at $911.0 million in Q1 2024 and troughed at -$1.3 billion in Q4 2024.
• A 5-year average of -$7.9 million and a median of $25.0 million in 2022 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 548673.49% in 2024, down 733562.66% in 2024.
• Over 5 years, Common Equity stood at $538.8 million in 2022, then fell by 20.56% to $428.0 million in 2023, then plunged by 414.44% to -$1.3 billion in 2024, then jumped by 103.87% to $52.1 million in 2025, then surged by 148.69% to $129.5 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $129.5 million, $52.1 million, and -$17.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.